(Press-News.org) JUPITER, FL, February 11, 2011 – Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.
Although the findings were in animal models of the disease, the effectiveness of the compound, combined with its potential to be taken orally, offers the tantalizing possibility of a potentially useful future therapy for Parkinson's disease patients.
The results were published in two separate studies in the journal ACS Chemical Neuroscience.
"These studies present compelling data on the first oral, brain-penetrating inhibitor to show significant efficacy in preventing neurodegeneration in both mouse and rat models of Parkinson's disease," said team leader Philip LoGrasso, a professor in the Department of Molecular Therapeutics and senior director for drug discovery at Scripps Florida. "The compound offers one of the best opportunities we have for the development of an effective neuroprotective treatment."
The new small molecule—labeled SR-3306—is aimed at inhibiting a class of enzymes called c-jun-N-terminal kinases (JNK). Pronounced "junk," these enzymes have been shown to play an important role in neuron (nerve cell) survival. As such, they have become a highly viable target for drugs to treat neurodegenerative disorders such as Parkinson's disease.
"A drug like SR-3306 that prevents neurodegeneration would be a quantum leap in the clinical treatment of Parkinson's because all current therapies treat only the symptoms of the disease, not the underlying pathologies," LoGrasso said.
Patients with Parkinson's disease suffer from the loss of a group of neurons in the substantia nigra pars compacta (SNpc), part of the midbrain involved in motor control. These cells produce dopamine, a neurotransmitter that plays a key role in motor reflexes and cognition. The disease also affects projecting nerve fibers in the striatum, a part of the forebrain filled with cells that interact with dopamine.
Stopping the Progression of Neuron Destruction in Animal Models
The SR-3306 compound, which has been in development at Scripps Florida for several years, performed well in both cell culture and animal models. In cell culture, the compound showed greater than 90 percent protection against induced cell death of primary dopaminergic neurons, while in mouse models of induced neuron death, the compound showed protective levels of approximately 72 percent.
The scientists went one step further, testing the new compound in a rat model, which duplicates the physical symptoms often seen with the human disease—a pronounced and progressive loss of motor skills. The results showed SR-3306 provided a protection level of approximately 30 percent in the brain, a level that reduced the dysfunctional motor responses by nearly 90 percent.
"It was a surprise that level of neuroprotection reduced the behavioral impact so strongly," LoGrasso said, "but it's indicative of how it might perform in human patients. While SR-3306 doesn't represent a cure, it does appear to have the potential of stopping the progression of the disease."
The new studies are part of a $7.6 million multiyear grant awarded to LoGrasso in 2008 by the National Institutes of Neurological Disorders and Stroke (NINDS). The grant will enable Scripps Research and potential partners to file an application for an investigational new drug (IND)—the first step in the lengthy clinical trials process required by the U.S. Food and Drug Administration before a new drug can be brought to market.
INFORMATION:
The first authors of the study, "Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease," are Jeremy W. Chambers and Alok Pachori of Scripps Research. Other authors include Shannon Howard, Michelle Ganno, Donald Hansen Jr., Ted Kamenecka, Xinyi Song, Derek Duckett, Weimin Chen, Yuan Yuan Ling, Lisa Cherry, Michael D. Cameron, Li Lin, and Claudia H. Ruiz, also of Scripps Research. See http://pubs.acs.org/doi/abs/10.1021/cn100109k .
The first author of the study, "JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-hydroxydopamine Model of Parkinson's Disease," is Candice E. Crocker of Dalhousie University, Halifax, Nova Scotia, Canada. Other authors include Susan Khan and Michael D. Cameron of Scripps Research, and Harold A. Robertson and George S. Robertson of Dalhousie. See http://pubs.acs.org/doi/abs/10.1021/cn1001107 .
Both studies were supported by the National Institutes of Health. Harold A. Robertson and George S. Robertson were supported by funding from the Atlantic Innovation Fund.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Headquartered in La Jolla, California, Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and synthetic vaccine development, as well as autoimmune, cardiovascular, and infectious disease. The institute also includes a campus in Jupiter, Florida, where scientists focus on basic biomedical science, drug discovery, and technology development. Scripps Research currently employs approximately 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu .
END
Tiny gold particles can help doctors detect tumor cells circulating in the blood of patients with head and neck cancer, researchers at Emory and Georgia Tech have found.
The detection of circulating tumor cells (CTCs) is an emerging technique that can allow oncologists to monitor patients with cancer for metastasis or to evaluate the progress of their treatment. The gold particles, which are embedded with dyes allowing their detection by laser spectroscopy, could enhance this technique's specificity by reducing the number of false positives.
The results are published ...
LOS ANGELES, CALIF. – Home-based physical therapy to improve the strength and balance of stroke survivors works about as well to get them walking again as treadmill training done in a physical therapy lab, according to the results of a study presented today by a Duke researcher at the American Stroke Association's International Stroke Conference.
"We have been working for years in rehabilitation to develop the most effective interventions for walking recovery," said Pamela Woods Duncan, Ph.D., PT, professor in the Doctor of Physical Therapy Division at Duke University ...
Frozen credit markets are adversely impacting the multi-billion dollar franchising industry. The lack of bank loans for franchised businesses is the major factor preventing the sale of new franchises. Further, this national credit crunch is stopping the re-sale of existing franchises, from franchisee to franchisee.
"Transfers (re-sales) are a healthy part of every franchise system. But the nation's lack of bank lending to buyers of existing franchises threatens the ability of franchise systems to rejuvenate their networks through new franchisees. This reduction in transfers ...
A unique new probe based on luciferase, the enzyme that gives fireflies their glow, enables researchers to monitor hydrogen peroxide levels in mice and thereby track the progression of infectious diseases or cancerous tumors without harming the animals or even having to shave their fur. Developed by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley, this new bioluminescent probe has already provided the first direct experimental evidence that hydrogen peroxide is continuously made even in a healthy ...
Konnessi LLC, a Rhode Island web design and marketing strategies company, has relocated its Providence offices into the Churchill and Banks building at 10 Greene Street. The move, which took effect on January 1, 2011, marks not only a major upgrade in office facilities and capabilities for the company, but also a migration deeper into the downtown Providence district.
Founded recently in 2010, the RI web design firm Konnessi (which in Maltese means, "connected") has seen exponential growth both in employees and in clientele, all in just under a year of existence. With ...
Children with attention-deficit hyperactivity disorder are two to three times more likely than children without the disorder to develop serious substance abuse problems in adolescence and adulthood, according to a study by UCLA psychologists and colleagues at the University of South Carolina.
"This greater risk for children with ADHD applies to boys and girls, it applies across race and ethnicity — the findings were very consistent," said Steve S. Lee, a UCLA assistant professor of psychology and lead author of the study. "The greater risk for developing significant ...
Has Valentine's Day become post-racial? Not yet, it seems.
New research from the University of California, Berkeley, suggests that when it comes to dating, cyberspace is as segregated as the real world. Data gathered from more than 1 million profiles of singles looking for love online show that whites overwhelmingly prefer to date members of their own race, while blacks, especially men, are far more likely to cross the race barrier in hopes of being struck by Cupid's arrow.
UC Berkeley researchers analyzed the racial preferences and online activity of people from the ...
Sitrof Technologies is pleased announced the end customer, Copernicus Group IRB (CGIRB) was named a finalist for the 2011 AIIM Best Practices Award. The Carl E. Nelson Best Practices Award was established to recognize excellence in information management.
Sitrof Technologies implementation of Xerox Corporation's (NYSE:XRX) DocuShare enterprise content management (ECM) was recognized as a finalist in the Small Company category for their work in transforming Copernicus Group IRB into a paperless company. CGIRB is now 96% paperless after the 2 year implementation. The paperless ...
Troy, N.Y. – Peter Fox and James Hendler of Rensselaer Polytechnic Institute are calling for scientists to take a few tips from the users of the World Wide Web when presenting their data to the public and other scientists in the Feb. 11 issue of Science magazine. Fox and Hendler, both professors within the Tetherless World Research Constellation at Rensselaer, outline a new vision for the visualization of scientific data in a perspective piece titled "Changing the Equation on Scientific Data Visualization."
As the researchers explain, visualizations provide a means to ...
CORVALLIS, Ore. — The application of a naturally occurring pheromone to honey bee test colonies increases colony growth resulting in stronger hives overall, according to a new study conducted by scientists at Oregon State University and Texas A&M University.
The study, which appeared this week in the journal, PLoS ONE, comes amid national concern over the existence of honey bee Colony Collapse Disorder (CCD) – a combination of events that result in the death of a bee colony. The causes behind CCD remain unknown, but researchers are focusing on four possible contributing ...
